Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

Research

Prevalence of rheumatic heart disease in young adults from New Caledonia

The prevalence of echocardiographically diagnosed RHD in adults in New Caledonia is estimated at 5.9 per 1000

Research

Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukaemia

Several studies suggest that maternal folic acid supplementation before or during pregnancy protects against childhood acute lymphoblastic leukaemia (ALL).

Sharing vision and responsibility

Minderoo Foundation and The Kids join forces to give children the best possible start.

Vaccine and immunisation trials pivotal in the fight against potentially deadly virus

As a leading research site in Australia, the Wesfarmers Centre of Vaccines and Infectious Diseases played an instrumental role in the global effort to develop a world-first RSV immunisation for young babies.

Key research helps inform policy on e-cigarettes

Formative research undertaken by The Kids Research Institute Australia has helped inform tough new laws introduced by the Federal Government to reduce the harm caused by vapes.

Research

Nasopharyngeal density of respiratory viruses in childhood pneumonia in a highly vaccinated setting: findings from a case-control study

Detection of pneumonia-causing respiratory viruses in the nasopharynx of asymptomatic children has made their actual contribution to pneumonia unclear. We compared nasopharyngeal viral density between children with and without pneumonia to understand if viral density could be used to diagnose pneumonia.

Research

Human genetics of leishmania infections

GWAS results provide firm confirmation for the importance of antigen presentation and the regulation of IFNγ in determining the outcome of Leishmania infections

Research

Panel 4: Recent advances in understanding the natural history of the otitis media microbiome and its response to environmental pressures

Advances in understanding bacterial dynamics in the upper airway microbiome are driving development of microbiota-modifying therapies to prevent or treat disease